FDA Approves J&J’s Tecrentriq for Blood Cancer
FDA Approves J&J’s Tecrentriq for Blood Cancer The US Food and Drug Administration (FDA) has approved Janssen Biotech’s blood cancer therapy, tecrentriq (dostarlimab). Tecrentriq is a first-in-class therapy that targets a specific protein that is involved in the growth of cancer cells. Tecrentriq is approved for the treatment of adults with relapsed or refractory multiple…